Close menu




December 9th, 2019 | 07:40 CET

Aphria, Aurora Cannabis, Canopy Growth - What Investors Need to Know in December

  • Cannabis
Photo credits: pixabay.com

Investors around the globe have become acquainted with a new industry in recent years: cannabis. It is actually an old plant, but the effects attributed to it have sparked a new trend and brought a variety of applications in various products to market. From Canada, the hype was significantly supported and from there producers have conquered the world - provided that the legal framework for the production, processing or distribution of cannabis products has already been created. After a long phase of rising share prices, the last thing to follow was a hangover mood. Why is December a special month?

time to read: 1 minutes | Author: Mario Hose
ISIN: CA05156X1087 , CA1380351009 , CA03765K1049

Table of contents:


    Sales at the end of the year 2019

    The shares of Aphria have traded between CAD 4.76 and CAD 14.37 over the past 12 months. On Friday, the stock was traded at 6.22 CAD on the Toronto Stock Exchange and recovered significantly from its low around four weeks ago. The stock market value of the cannabis company Aphria at the end of the previous week was CAD 1.57 billion.

    At Aurora Cannabis the price development tends to be comparable. The company's shares have been traded between CAD 2.82 and CAD 13.67 since December 2018. Their shares also reached its low for the year around four weeks ago. On Friday, the shares were traded at CAD 3.21 and gave the company a market value of CAD 3.50 billion.

    Second row enticing with potential

    Canopy Growth, with a market capitalization of CAD 8.61 billion, is the heavyweight among the listed companies in the cannabis industry. Canopy Growth shares have traded from CAD 18.23 to CAD 70.98 over the past 12 months. The indication that the lowest level was reached in the past four weeks is a mere formality. On Friday, the Canopy Growth shares were trading at 24.72 CAD.

    There are also exciting second-tier companies that do not yet have to defend a billion-dollar valuation, but are working towards the big breakthrough next year. The developer of cannabis drinks, BevCanna Enterprises, currently has less than CAD 20 million market capitalization and the producer of cannabis in Africa, EXMceuticals, less than CAD 30 million. The two newcomers have promising and scalable business models.

    End of the year offers bargains

    Investors wishing to position themselves in cannabis may have a particularly interesting window of opportunity for their exposure in the current month of December. Tax Loss Season is a term for experienced investors that stands for tax optimization. The phenomenon of shareholders throwing their loss positions onto the market is a recurring year-end ritual, especially in Canada.

    This development is clear in the case of listed companies that have suffered greater price losses in recent months. The chart trend of a loss in value often ends in a panicky sell-off in December. As is well known, the profits lie in purchasing and bargain hunters can get their money's worth with low limits.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read

    Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

    Ayurcann, Novavax, Covestro - The stragglers are coming!

    • Cannabis

    Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

    Read

    Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

    Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

    • Cannabis

    About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

    Read